BiondVax Pharmaceuticals Ltd. recently gained approval for its Multimeric Multi-Epitope Polypeptide Influenza Vaccines series patent in South Korea.
This approval from the Korean Intellectual Property Office will expand and strengthen the intellectual property portfolio for BiondVax around the world. The approval applies to M-001 and other polypeptides.
Other countries (Australia, China,
Hong Kong, European nations,
Japan, Mexico, Russia, and the U.S.) have already approved the vaccine.
The company uses its unique, proprietary combination of common and conserved peptides within influenza virus proteins to provoke a response from the immune system. This will generate a cross-protecting and long-lasting effect to protect people from the virus.
The patent is specifically designed to protect people from contracting influenza from several different strains of the virus. This could be the universal flu vaccine that the health community has been anticipating. The vaccine should protect people across seasons and influenza strains, whether they are pandemic or seasonal.
“Asia has been the site of the start of many recent bird-flu pandemics, including H5N1 and H7N9,”
BiondVax CEO Ron Babecoff said. “Our new patent approval in Korea provides us with an opportunity to establish a strategic partnership in this market. This will enable us to offer local health authorities and governments our pandemic preparedness plan, with the establishment of national stockpiles against all types of influenza pandemics.”
